Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Significances of NEDD-9 and FOXL-1 Expression in Intestinal Type Gastric Carcinoma: an Immunohistochemical Study

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Gastric cancer (GC) is mostly diagnosed at advanced stage, so prognosis is poor. Therefore, it is necessary to understand the molecular mechanism of GC development to design new targeted treatment to improve the prognosis of gastric cancer patients.

Aim of the Work

To assess the prognostic value of NEDD-9 and FOXL-1 expression in intestinal type gastric cancer patients, as well as their relationship to clinicopathologic features of the disease and patients outcome.

Patients and Methods

This is a retrospective study; we included 50 sections from formalin-fixed, paraffin-embedded tissue samples which included intestinal type GC and adjacent non-neoplastic gastric mucosa in the same block that were subjected to immunohistochemistry with anti-NEDD-9 and anti-FOXL-1 antibody. Patients were retrospectively followed up for about 5 years for assessment of tumor progression and survival in relation to marker expression.

Results

High NEDD-9 and low FOXL-1 expression were found in intestinal type GC more than adjacent non-neoplastic mucosa (p < 0.001). NEDD-9 high expression and FOXL-1 low expression were associated with presence of helicobacter pylori gastritis (p = 0.010, 0.049), high grade (p = 0.007, 0.004), high stage (p < 0.001), presence of distant metastases (p = 0.029, 0.021), poor DFS (p = 0.003), and OS rates (< 0.001).

Conclusion

NEDD-9 overexpression and FOXL-1 deficiency in intestinal type GC can help in prediction of tumor prognosis and it can guide the selection of patients for future therapies in gastric carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  Google Scholar 

  3. Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer (review). Oncol Lett. 2016;16:2959–64.

    Article  Google Scholar 

  4. Rugge M, Genta RM, di Mario F, Mf D, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 2017;15(12):1833–184.

    Article  Google Scholar 

  5. Wang K, Yuen ST, Xu J, Lee SP, Yan HHN, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–82.

    Article  CAS  Google Scholar 

  6. Cho JY. Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer. 2013;13:129–35.

    Article  Google Scholar 

  7. Singh M, Cowell L, Seo S, et al. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007;48:54–72.

    Article  CAS  Google Scholar 

  8. Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015;567:1–11.

    Article  CAS  Google Scholar 

  9. Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer. 2013;13:482–95.

    Article  CAS  Google Scholar 

  10. Fukuda K, Yoshida H, Sato T, Furumoto TA, Mizutani-Koseki Y, Suzuki Y, et al. Mesenchymal expression of Foxl1, a winged helix transcriptional factor, regulates generation and maintenance of gut associated lymphoid organs. Dev Biol. 2003;255:278–89.

    Article  CAS  Google Scholar 

  11. Amin MB, Greene FL, Edge SB, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.

    Article  Google Scholar 

  12. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J HistochemCytochem. 1981;29:577–80.

    CAS  Google Scholar 

  13. Chang J, Gao F, Zhao G, Zhang G. Expression and clinical significance of NEDD9 in lung tissues. Med Oncol. 2012;29(4):2654–60.

    Article  CAS  Google Scholar 

  14. Yang FQ, Yang FP, Li W, Liu M, Wang GC, Che JP, et al. Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer. Int J Clin Exp Pathol. 2014;7(1):110–22.

    PubMed  Google Scholar 

  15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;l119:1420–8.

    Article  Google Scholar 

  16. Zhou S, Xu M, Shen J, Liu X, Chen M, Cai X. Overexpression of NEDD9 promotes cell invasion and metastasis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41:677–86.

    Article  CAS  Google Scholar 

  17. Guerrero MS, Parsons JT, Bouton AH. Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton. Genes Cancer. 2012;3(5–6):371–81.

    Article  CAS  Google Scholar 

  18. Li P, Sun T, Yuan Q, Pan G, Zhang J, Sun D. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients. Onco Targets Ther. 2016;9:5751–9.

    Article  CAS  Google Scholar 

  19. Miao Y, Li A-L, Wang L, Fan CF, Zhang XP, Xu HT, et al. Overexpression of NEDD9 is associated with altered expression of E-cadherin, β-catenin and N-cadherin and predictive of poor prognosis in non-small cell lung cancer. Pathol Oncol Res. 2013;(2):281–6.

  20. Wang J, Wang S, Luan Y, Zhang W, Sun C, Cheng G, et al. Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion. Oncol Lett. 2017;14:8021–7.

    PubMed  PubMed Central  Google Scholar 

  21. Wang Z, Shen M, Lu P, Li X, Zhu S, Yue S. NEDD9 may regulate hepatocellular carcinoma cell metastasis by promoting epithelial-mesenchymal-transition and stemness via repressing Smad7. Oncotarget. 2017;8:1714–24.

    Article  Google Scholar 

  22. Li P, Zhou H, Zhu X, Ma G, Liu C, Lin B, et al. High expression of NEDD9 predicts adverse outcomes of colorectal cancer patients. Int J Clin Exp Pathol. 2014;7:2565–70.

    PubMed  PubMed Central  Google Scholar 

  23. Wang H, Mu X, Zhou S, Zhang J, Dai J, Tang L, et al. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer. Hum.Pathol. 2014;45:401–8.

    Article  Google Scholar 

  24. Feng J, Zhao J, Xie H, Yin Y, Luo G, Zhang J, et al. Involvement of NEDD9 in the invasion and migration of gastric cancer. Tumour Biol. 2015;36:3621–8.

    Article  CAS  Google Scholar 

  25. Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, et al. Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol. 2014;31:33.

    Article  Google Scholar 

  26. Shi R, Wang L, Wang T, Xu J, Wang F, Xu M. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol. 2014;31:852.

    Article  Google Scholar 

  27. Zhang SS, Wu LH, Liu Q, Chen KS, Zhang XF. Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer. OncoTargets and therapy. 2015;8:633–40.

    PubMed  PubMed Central  Google Scholar 

  28. Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, et al. NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol. 2014;35:6351–6.

    Article  CAS  Google Scholar 

  29. Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene. 2011;30:2633–43.

    Article  CAS  Google Scholar 

  30. Zhao S, Min P, Liu L, Zhang L, Zhang Y, et al. NEDD9 facilitates hypoxia-induced gastric cancer cell migration via MICAL1 related Rac1 activation. Front Pharmacol. 2019:10–291.

  31. Li Z, Li L, Wu C, Wang Z, et al. NEDD9 is a novel prognostic marker in gastric cancer patients. Int J Clin Exp Pathol. 2017;10(3):3456–60.

    CAS  Google Scholar 

  32. Gu Y, Lu J, Chen C, Zheng F. NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis. Onco Targets Ther. 2019 May 28;12:4213–22.

    Article  CAS  Google Scholar 

  33. Ertao Z, Jianhui C, Chuangqi C, Changjiang Q, Sile C, et al. Low level of FOXL1 indicates a worse prognosis for gastric cancer patients. Tumour Biol. 2016;37:11331–7.

    Article  Google Scholar 

  34. Perreault N, Sackett SD, Katz JP, Furth EE, Kaestner KH. Foxl1 is a mesenchymal modifier of Min in carcinogenesis of stomach and colon. Genes Dev. 2005;19:311–5.

    Article  CAS  Google Scholar 

  35. Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, et al. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res. 2013;73:5416–25.

    Article  CAS  Google Scholar 

  36. Qin Y, Gong W, Zhang M, Wang J, Tang Z, Quan Z. Forkhead box L1 is frequently downregulated in gallbladder cancer and inhibits cell growth through apoptosis induction by mitochondrial dysfunction. PLoS One. 2014;9:e102084.

    Article  Google Scholar 

  37. Chen X, Deng M, Ma L, Zhou J, Xiao Y, Zhou X, et al. Inhibitory effects of forkhead box L1 gene on osteosarcoma growth through the induction of cell cycle arrest and apoptosis. Oncol Rep. 2015;34:265–71.

    Article  Google Scholar 

  38. Xue Y, Wu T, Dai Y, Sheng YY, Wu YM, Xia BL, et al. NEDD9 expression is correlated with epithelial-to-mesenchymal transition markers in colorectal cancer. Int J Clin Exp Pathol. 2017;10(8):8640–6.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt

    Noha F. Elaidy & Ola A. Harb

  2. Department of Clinical Oncology& Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Abdel Motaleb Mohamed & Rehab Hemeda

  3. Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Heba F. Taha

  4. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Amr Samir

  5. Department of Tropical Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Ahmed M. Elsayed

  6. Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Gamal Osman & Elsayed I El. Hendawy

Authors
  1. Noha F. Elaidy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola A. Harb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdel Motaleb Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rehab Hemeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Heba F. Taha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amr Samir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmed M. Elsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gamal Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elsayed I El. Hendawy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ola A. Harb.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elaidy, N.F., Harb, O.A., Mohamed, A.M. et al. Prognostic Significances of NEDD-9 and FOXL-1 Expression in Intestinal Type Gastric Carcinoma: an Immunohistochemical Study. J Gastrointest Canc 52, 728–737 (2021). https://doi.org/10.1007/s12029-020-00471-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00471-3

Keywords

Search

Navigation